Company Filing History:
Years Active: 2009
Title: **Ti Cai: Innovating Tumorigenic Mouse Cell Development**
Introduction
Ti Cai, an innovative inventor based in Andover, MA, has made significant contributions to scientific research, particularly in the field of oncology. With a focus on creating advanced methodologies to better understand tumorigenesis, his work aims to enhance the study of cancer and therapeutic interventions.
Latest Patents
Ti Cai holds a patent for a groundbreaking method of producing tumorigenic mouse cells that rely on a recombinant gene of interest. This patent, titled "Directed complementation," outlines a process where a conditionally tumorigenic mouse cell contains a recombinant oncogene linked to an inducible promoter. The invention allows for the tumorigenicity of these cells to depend on a recombinant gene that complements the oncogene, providing a novel approach for testing compounds for anti-tumor effects. By implanting these engineered cells in mice and administering various test compounds, researchers are enabled to assess their therapeutic potential effectively.
Career Highlights
Ti Cai is currently associated with Aveo Pharmaceuticals, Inc., a prominent biopharmaceutical company dedicated to delivering targeted therapies for cancer treatment. His role at the company has been pivotal in advancing research that merges molecular biology with pharmacology, contributing to the creation of more efficient cancer treatment methods.
Collaborations
Throughout his career, Ti has collaborated with esteemed colleagues including Murray Robinson and Ronan O'Hagan. These partnerships signify a strong collaborative spirit within the research community, as they work together to expand the boundaries of cancer research and therapy development.
Conclusion
Ti Cai showcases the quintessential characteristics of an inventor – innovation, collaboration, and dedication to scientific advancement. His contributions, particularly through his patent on tumorigenic mouse cells, have paved the way for significant developments in cancer research, enabling the exploration of new therapeutic options. As the fight against cancer continues, Ti’s work remains an essential component in the ongoing quest for effective treatments.